Lifeboat Foundation

Nice interview by The Longevity Reporter about BioViva Sciences Inc.

Liz Parrish isn’t your average CEO. A passionate advocate for change, her.
company BioViva is leading the fight for healthy longevity with pioneering.
gene therapies targeting Alzheimer’s, sarcopenia and even aging itself.
Parrish dreams big, but she’s a woman of action. She’s even demonstrated.
her commitment by testing cutting-edge therapies on herself. Could her.
efforts change how we think about aging? Is gene therapy the future or are.
we moving too fast? We caught up with the woman herself to find out more.

Read more

After a 10 year study of 3000 people, researchers have made the surprising discovery that hearts age differently in men and women.

We need personalised medicine

We know people age differently, both inside and outside. This is down to a complex interplay of genetics and environment, which leads to significant variation in the aging process for all of us. What we didn’t expect was that such a striking difference would emerge between the genders. So what does this mean? Could there be more we’re missing?

Read more

The much pursued fountain of youth can become a reality if humans agree to share their DNA information, according to Google Ventures’ CEO Bill Maris, who has warned that “we’re all going to die” earlier if we keep our genetic codes secret.

Maris, who aims to digitize DNA, stressed during a Wall Street Journal technology conference in California that our genomes “aren’t really secret,” urging those protective of their genetic information to loosen the reins a bit.

Noting that genetic material is constantly left lying around in public, Maris addressed those who remain nervous about the digitization of DNA. “What are you worried about?” he said on Tuesday, adding that a person could easily gather information by fishing a used cup out of the trash and taking it to a lab for analysis.

Read more

To whom it may concern,

Cryonics is a legitimate science-based endeavor that seeks to preserve human beings, especially the human brain, by the best technology available. Future technologies for resuscitation can be envisioned that involve molecular repair by nanomedicine, highly advanced computation, detailed control of cell growth, and tissue regeneration.

With a view toward these developments, there is a credible possibility that cryonics performed under the best conditions achievable today can preserve sufficient neurological information to permit eventual restoration of a person to full health.

Read more

Austin’s (Texas) leading paper features features transhumanism, biohacking, and longevity near the bottom:

Yesterday began with a 7:30 a.m. call from Dr. Ben Carson for what I thought was a pretty good half hour interview about his new book, A More Perfect Union, his primer on the Constitution, which I read over the weekend.

I was pleased.

Continue reading “A tale of two buses: On Ben Carson, Zoltan Istvan, millennialism and eternal life” »

Dr Michael Fossel comments on the recent Bioviva announcement of the first human gene therapy against aging.

The other day, a friend of mine, Liz Parrish, the CEO and founder of BioViva, made quite a splash when she injected herself with a viral vector containing genes for both telomerase and FST. Those in favor of what Liz did applaud her for her courage and her ability to move quickly and effectively in a landscape where red tape and regulatory concerns have – in the minds of some – impeded innovation and medical care. Those opposed to what Liz did have criticized her for moving too rapidly without sufficient concern for safety, ethics, or (from some critics) scientific rationale.

Many people have asked me to comment, both as an individual and as the founder of Telocyte. This occurs for two reasons. For one thing, I was the first person to ever advocate the use of telomerase as a clinical intervention, in discussions, in published journal articles, and in published books. My original JAMA articles (1997 and 1998), my first book on the topic (1996), and my textbook (2004) all clearly explained both the rational of and the implications for using telomerase as a therapeutic intervention to treat age-related disease. For another thing, Liz knew that our biotech firm, Telocyte, intends to do almost the same thing, but with a few crucial differences: we will only be using telomerase (hTERT) and we intend to pursue human trials that have FDA clearance, have full IRB agreement, and meet GMP (“Good Medical Production”) standards.

We cannot help but applaud Liz’s courage in using herself as a subject, a procedure with a long (and occasionally checkered) history in medical science. Using herself as the subject undercuts much of the ethical criticism that would be more pointed if she used other patients. Like many others, we also fully understand the urgent need for more effective therapeutic interventions: patients are not only suffering, but dying as we try to move ahead. In the case of Alzheimer’s disease, for example (our primary therapeutic target at Telocyte), there are NO currently effective therapies, a history of universal failure in human trials for experimental therapies, and an enormous population of patients who are currently losing their souls and their lives to this disease. A slow, measured approach to finding a cure is scarcely welcome in such a context.

Read more

What the nervous system of the roundworm, frozen embryos, and extreme hypothermia tell us about preserving the mind.

Read more

The first attempt at using gene therapy to prevent regular aging allegedly happened last month in what could spell the beginning of a new era in do-it-yourself genetic modification.

CEO and founder of BioViva Sciences USA Inc, Liz Parrish, claims she underwent gene therapy at an undisclosed location in Latin America where she received two forms of treatment, including muscle mass enhancement and therapy to increase the length of the telomeres, the DNA caps which protect the chromosome from deterioration and are associated with longer life span.

Parrish announced in a Reddit AMA that she had gone through the therapy and if successful she plans to roll out a public offering in three to five years despite neither treatment being FDA approved. The results of the therapy are yet unknown and she says she feels no different so far but believes it will be months before any changes occur. If successful her body, in theory, should begin to de-age.

Read more

We all have different circadian rhythms but they slow down during aging, and we may be able to do something about it.

Your body is in a state of constant flux and the circadian rhythm is its master regulator, controlling everything from sleep cycles to appetite and beyond. Jet lag is a side effect of a confused internal cycle as it adjusts to a new timetable. Shift work and irregular patterns of activity can also potentially cause some serious problems if sustained for a long period, including raising risk of type 2 diabetes, dementia and all cause mortality.

When researchers studied aging mice, they saw a progressive decline in levels of molecules called polyamines. These are involved with a number of processes, but particularly in cell growth and circadian rhythm. The drop in polyamines also coincided with a slowing of their circadian cycle — which increased disease risk.

Read more